bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2017: N O S A J J M A M F J
2016: D N

 
  Other news for:
Leukemia
 Resources from HONselect
Zelboraf Approved for Rare Blood Cancer

By Scott Roberts

MONDAY, Nov. 6, 2017 (HealthDay News) -- Zelboraf (vemurafenib) has been approved by the U.S. Food and Drug Administration as the first drug to treat Erdheim-Chester Disease, a rare but deadly blood cancer. The approval covers patients who have a genetic mutation called BRAF V600.

Erdheim-Chester Disease is a slow-growing cancer that originates in bone marrow, causing a spike in a type of white blood cell called a histiocyte. This can spur tumors that develop in the heart, lung, brain and elsewhere, the FDA said Monday in a news release. The cancer only affects about 700 people worldwide, about half of whom have the BRAF V600 mutation.

Life expectancy is short among patients, the agency said.

"This [drug] was first approved in 2011 to treat certain patients with melanoma [skin cancer] that harbor the BRAF V600 mutation, and we are now bringing the therapy to patients with a rare cancer with no approved therapies," said Dr. Richard Pazdur, director of the agency's Oncology Center of Excellence.

Zelboraf is a kinase inhibitor that's designed to inhibit enzymes that spur cancer cell growth. The most common side effects include joint pain, skin rash, hair loss, fatigue and heart problems, the FDA said.

Less common but more severe adverse reactions could include development of other cancers, severe skin reactions, liver damage and kidney failure. Pregnant women shouldn't take the drug, since it could harm a developing fetus, the FDA said.

The drug is produced by the Swiss pharmaceutical firm Hoffman-LaRoche.

SOURCE: Nov. 6, 2017 press release, U.S. Food and Drug Administration

Copyright © 2017 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=728264

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Neoplasms
Blood
Heart
Bone Marrow
Exanthema
Cells
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact